Retatrutide is contraindicated in individuals with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis history, or uncontrolled cardiovascular disease
Retatrutide: A Comparison Mechanism of Action: Semaglutide: This medication is a glucagon-like peptide-1 (GLP-1) receptor agonist
Back GBD 2019 Risk Factor Collaborators (2020) 'Global Burden of 87 Risk Factors in 204 Countries and Territories, 19902019: a systematic analysis for the global burden of disease study 2019', The Lancet , 396, 122349
I believe period tracking apps could and should play a role in the monitoring of hormonal health in patients taking new medications, primarily because these apps collect information over time directly from the person using them, helping to spot trends, unusual events, and individual differences
These regulations exist to ensure that medicinal products like Retatrutide are only used in a controlled, safe, and ethical manner, particularly within the context of approved clinical research